BioSpace News Archive

Business

UK’s Wellcome Trust to Invest $330 Million into High-Risk Life Science Research

The UK’s Wellcome Trust, a charitable foundation, announced it is creating the $330 million Leap Fund to invest in high-risk healthcare and life science research.

July 10, 2018
·
3 min read
·
Mark Terry
Business

Xtant Medical Appoints Kevin Brandt as Chief Commercial Officer

Xtant Medical Holdings, Inc. announced the appointment of Kevin Brandt to the new executive position of Chief Commercial Officer effective July 9, 2018.

July 10, 2018
·
4 min read
Policy

Takeda Receives Clearance from the United States Federal Trade Commission for the Proposed Acquisition of Shire plc

Takeda Pharmaceutical Company Limited announces that it has received unconditional clearance from the United States Federal Trade Commission (“FTC”) for the proposed acquisition of Shire plc announced on May 8, 2018 (the “Acquisition”).

July 10, 2018
·
5 min read
Deals

Sofinnova Partners Announces the Sale of ReCor Medical to Otsuka Holdings

Sofinnova Partners today announced that Otsuka Holdings is acquiring its portfolio company ReCor Medical.

July 10, 2018
·
5 min read
Business

Relay Therapeutics Names Steven Kafka to Its Board of Directors

Relay Therapeutics announced the appointment of Steven Kafka, Ph.D., to its board of directors.

July 10, 2018
·
2 min read
Drug Development

Arbutus Presents Corporate Update on Key Milestones

Arbutus Biopharma Corporation today announced updates on several key milestones in advance of the company’s presentation at Roivant Pipeline Day in New York City this afternoon.

July 10, 2018
·
7 min read
Drug Development

Recursion Receives FDA Clearance of Investigational New Drug Application to Initiate First Clinical Trial of REC-994 in Cerebral Cavernous Malformation

Recursion announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase 1 clinical trial of REC-994 in the treatment of cerebral cavernous malformation (CCM).

July 10, 2018
·
3 min read
Drug Development

ArmaGen’s AGT-181 52-Week Phase 1/2 Proof-of-Concept Study Results Published in Orphanet Journal of Rare Diseases

Novel Fusion Protein Demonstrates Neurocognitive Benefit in Children with Severe Mucopolysaccharidosis Type I (MPS I, or Hurler Syndrome), with Favorable Safety Profile

July 10, 2018
·
7 min read
Job Trends

Medical Device Startup HeartHero Closes Seed Round Of Funding

Milestone Brings Company One Step Closer to Saving Lives

July 10, 2018
·
2 min read
Business

Cardiovascular Systems, Inc. to Release Fiscal 2018 Fourth-Quarter Results on July 30

Webcast of analyst day on July 31 will include discussion of fiscal fourth-quarter results.

July 10, 2018
·
1 min read